Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

@article{Nolan2018EvolutionOV,
  title={Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.},
  author={Rachel C. Nolan and Omar Akhand and John-Ross Rizzo and Steven L. Galetta and Laura Joan Balcer},
  journal={Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society},
  year={2018},
  volume={38 2},
  pages={
          202-209
        }
}
: BACKGROUND:: The visual pathways are increasingly recognized as an ideal model to study neurodegeneration in multiple sclerosis (MS). Low-contrast letter acuity (LCLA) and optical coherence tomography (OCT) are validated measures of function and structure in MS. In fact, LCLA was the topic of a recent review by the Multiple Sclerosis Outcome Assessments… CONTINUE READING